Dr. Reddy's Laboratories Limited (RDY)
| Market Cap | 11.03B -0.5% |
| Revenue (ttm) | 3.85B +11.1% |
| Net Income | 629.75M +5.4% |
| EPS | 0.76 +5.6% |
| Shares Out | 832.57M |
| PE Ratio | 17.51 |
| Forward PE | 21.70 |
| Dividend | $0.07 (0.54%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 1,622,490 |
| Open | 13.40 |
| Previous Close | 13.26 |
| Day's Range | 13.31 - 13.60 |
| 52-Week Range | 12.38 - 16.17 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 16.90 (+26.97%) |
| Earnings Date | May 8, 2026 |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In fiscal year 2025, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial numbers in INR Financial StatementsAnalyst Summary
According to one analyst, the rating for RDY stock is "Strong Buy" and the 12-month stock price target is $16.9.
News
Dr. Reddy's Laboratories sells Svaas Wellness for Rs 2.23 crore
Dr. Reddy's Laboratories has announced the sale of its wholly owned subsidiary, Svaas Wellness Limited, for a total consideration of ₹2.23 crore. The agreement for the sale was finalised on…
Nifty 50 top losers today, April 7: Dr. Reddy's Laboratories, IndiGo, Adani Enterprises, Apollo Hospitals and more
Indian equity benchmarks closed higher on April 7, 2026, despite a volatile trading session, with the Nifty 50 ending above the 23,100 mark. However, selective profit booking was visible across…
Top gainers among Nifty 50 stocks in midday trades today, April 2: HCL Technologies up 1.1%, Dr. Reddy's Lab up 0.3%
IT stocks emerged as the top gainers among Nifty 50 constituents in midday trade on April 2, even as broader indices continued to trade lower during the session. As of…
Dr. Reddy's Laboratories issues 3,675 equity shares under ESOPs
Dr. Reddy's Laboratories has allotted 3,675 equity shares to eligible employees following the exercise of stock options under its Employees ADR Stock Options Scheme, 2007. The allotment took place on…
Dr Reddy's Laboratories Ltd (RDY) Trading 3.12% Higher on Mar 25
Dr Reddy's Laboratories Ltd (RDY) Trading 3.12% Higher on Mar 25
Setback for Dr Reddy’s as Delhi High Court asks company to halt Olympiq drug sales
The Delhi High Court today, March 25 directed Dr. Reddy’s Laboratories to immediately halt further sales and market expansion of its semaglutide-based diabetes drug under the brand name Olymviq Justic...
Dr. Reddy's Laboratories updates code for fair disclosure of price-sensitive information
Dr. Reddy's Laboratories has announced an update to its 'Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information'. This update aligns with the Securities and ...
Domestic companies launch semaglutide jabs at affordable prices
Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk's patent expiry. This move signif...
Dr. Reddy's Laboratories launches India's first DCGI-approved semaglutide injection
Dr. Reddy’s Laboratories has announced the launch of Obeda®, India’s first DCGI-approved semaglutide injection for Type 2 Diabetes. This launch marks Dr. Reddy’s Day-1 entry into the GLP-1 receptor ag...
Dr. Reddy's Laboratories updates on Eftilagimod Alfa trial discontinuation
Dr. Reddy's Laboratories has announced that Immutep's Independent Data Monitoring Committee recommended halting the TACTI-004 Phase III trial of Eftilagimod Alfa for non-small cell lung cancer. This d...
Dr. Reddy's Laboratories issues 10,275 equity shares under stock options scheme
Dr. Reddy's Laboratories has allotted 10,275 equity shares to eligible employees following the exercise of stock options under its employee stock option schemes. The shares, with a par value of…
What is dragging Dr Reddy’s shares 2% down today? Explained
Shares of Dr Reddy's Laboratories declined in early trade on Monday, March 9, as broader market weakness weighed on investor sentiment. As of 9:54 AM, the stock was trading at…
Top stocks to watch today, March 6: TCS, Tata Elxsi, GE Shipping, GRSE, Dr Reddy’s Lab, Mazagon Dock, Wipro, Bharat Forge, Angel One in focus
Several stocks are likely to remain in focus in Friday’s session on March 6, tracking corporate announcements, regulatory updates, stake transactions and sector-specific developments. Companies includ...
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's
TEVA, Sandoz and Dr. Reddy's are shifting toward complex generics and biosimilars to counter pricing pressure and strengthen margins in the competitive generics market.
Top losers among Nifty 50 stocks in midday trades today, Feb 27: Dr. Reddy’s falls 2.8%, Bharti Airtel down 2.7%, Grasim Industries drops 2.5%
Indian benchmark indices were trading lower in midday deals on February 27, reflecting broad-based selling pressure across sectors. As of...
Pharma sector stocks today, Feb 27: Dr. Reddys Lab down 1.14%, Cipla falls 1.04%, Natco Pharma up 1.09%
The Indian pharmaceutical sector showed mixed performance on February 27, 2026, during early morning trading hours. Data from around 9:24...
Citi flags Ozempic price cuts as negative for Dr Reddy’s generic Semaglutide uptake
Citi has maintained its Sell rating on Dr Reddy’s Laboratories with a target price of Rs 1,070, citing concerns around... Read the full article on Business Upturn
Dr. Reddy's (RDY) Biosimilar Application for Orencia Accepted by FDA
Dr. Reddy's (RDY) Biosimilar Application for Orencia Accepted by FDA
Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Abatacept--Dr. Reddy's announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.
Dr. Reddy’s Laboratories acquires Progynova and Cyclo-Progynova trademarks in India for $32.15 million
Dr. Reddy’s Laboratories Ltd. has announced the acquisition of the trademarks Progynova® and Cyclo-Progynova®, along with related assets for India,...
Top losers among Nifty 50 stocks in midday trades today, Feb 10: Shriram Finance, Bajaj Finance, Dr. Reddy’s, SBI Life and more
Indian equity benchmarks were trading modestly higher in midday deals on February 10, with the NIFTY up 0.35% at 25,958.85...
India-US trade deal clarity: Pharma exporters gain edge in US; sector eyes growth boost
Indian drugmakers anticipate significant benefits from the proposed India-US trade agreement, offering much-needed clarity and stability for the lucrative US pharmaceutical market. This development is...
Pharma stocks surge: Aurobindo Pharma jumps 5%, Dr Reddy’s and Divi’s Labs rise over 3%
Pharma stocks traded broadly higher in early deals on February 3, tracking strong momentum across the sector. As of 9:32...
Dr. Reddy's (RDY) Invests in Coya Therapeutics' Private Placement
Dr. Reddy's (RDY) Invests in Coya Therapeutics' Private Placement
Pharma sector stocks down today, jan 29: Dr. Reddy’s Lab drops 2.45%, Zydus falls 1.44%, Aarti Drugs down 1.86%
The Indian pharma sector showed mixed to negative performance on January 29, 2026, as of 10:18 AM IST, amid broader...